Analysts Conflicted on These Healthcare Names: Pfizer (PFE) and Chemomab Therapeutics (CMMB)
Confident Investing Starts Here:
Pfizer (PFE)
In a report released today, Trung Huynh from UBS maintained a Hold rating on Pfizer, with a price target of $25.00. The company's shares closed last Thursday at $24.84, close to its 52-week low of $24.48.
According to TipRanks.com, Huynh is a 5-star analyst with an average return of 13.3% and a 68.9% success rate. Huynh covers the Healthcare sector, focusing on stocks such as Acumen Pharmaceuticals, ALX Oncology Holdings, and Bristol-Myers Squibb.
Currently, the analyst consensus on Pfizer is a Moderate Buy with an average price target of $27.69, which is a 12.9% upside from current levels. In a report issued on June 4, Bernstein also maintained a Hold rating on the stock with a $30.00 price target.
In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on Chemomab Therapeutics, with a price target of $7.00. The company's shares closed last Thursday at $1.22.
According to TipRanks.com, Okunewitch is ranked 0 out of 5 stars with an average return of -17.0% and a 34.3% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Radiopharm Theranostics Limited Sponsored ADR, Acrivon Therapeutics, Inc., and Rani Therapeutics Holdings.
Currently, the analyst consensus on Chemomab Therapeutics is a Moderate Buy with an average price target of $8.50.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy?
Wall Street expects a year-over-year decline in earnings on higher revenues when Pfizer (PFE) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on August 5. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Zacks Consensus Estimate This drugmaker is expected to post quarterly earnings of $0.58 per share in its upcoming report, which represents a year-over-year change of -3.3%. Revenues are expected to be $13.78 billion, up 3.7% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 0.23% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for Pfizer? For Pfizer, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +1.43%. On the other hand, the stock currently carries a Zacks Rank of #3. So, this combination indicates that Pfizer will most likely beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that Pfizer would post earnings of $0.64 per share when it actually produced earnings of $0.92, delivering a surprise of +43.75%. Over the last four quarters, the company has beaten consensus EPS estimates four times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. Pfizer appears a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Expected Results of an Industry Player Another stock from the Zacks Large Cap Pharmaceuticals industry, AbbVie (ABBV), is soon expected to post earnings of $2.89 per share for the quarter ended June 2025. This estimate indicates a year-over-year change of +9.1%. Revenues for the quarter are expected to be $15.07 billion, up 4.2% from the year-ago quarter. The consensus EPS estimate for AbbVie has been revised 0.8% higher over the last 30 days to the current level. However, an equal Most Accurate Estimate has resulted in an Earnings ESP of 0%. When combined with a Zacks Rank of #3 (Hold), this Earnings ESP makes it difficult to conclusively predict that AbbVie will beat the consensus EPS estimate. The company beat consensus EPS estimates in each of the trailing four quarters. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Pfizer Inc. (PFE) : Free Stock Analysis Report AbbVie Inc. (ABBV) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Pfizer Stock Is a Value Play Ahead of Earnings - Investors Can Short PFE Puts for Income
Pfizer, Inc. (PFE) stock still looks cheap ahead of its upcoming Aug. 5 Q2 earnings release. Moreover, investors can make extra income by selling out-of-the-money (OTM) put options. This article updates my July 2 Barchart piece, 'Huge Unusual Volume in Pfizer Put Options Signals Investors Bullish Outlook.' More News from Barchart $200 AMD Price Target? Try These 2 Option Trades Before the Market Moves Option Volatility And Earnings Report For July 28 – Aug 1 Should You Grab This 'Strong Buy' Semiconductor Stock Ahead of Earnings? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! PFE stock is at $24.23 in midday trading on Tuesday, July 29. That's down from its March 7 high of $26.73. It could be worth substantially more, as this article will show. Statistically Cheap I demonstrated in my last article that PFE stock appears to be undervalued based on its historical price-to-earnings (P/E) ratio and analysts' earnings per share (EPS) forecasts. Additionally, based on its average historical dividend yield, PFE could rebound if it were to revert to its historical mean yield. Price-Earnings Target For example, analysts project $3.01 EPS this year and $3.08 in 2026. Barchart's analyst survey says the range is between $3.07 this year and $3.06 in 2026 - i.e., a slight decline in EPS. However, Yahoo! Finance reports a $3.01 EPS estimate for 2025 and $3.08 next year, and Stock Analysis says the analyst range is between $3.03 and $3.13. So, on average, these surveys range between $3.03 EPS this year and $3.09 next year. That means PFE stock is trading on a forward P/E multiple of between 8.0x (i.e., $24.23/$3.03) for 2025 and 7.84x ($24.23/$3.09). This is well below its historical valuation average. For example, Seeking Alpha reports that Pfizer stock has had an average 10.79x forward P/E multiple in the last 5 years. In addition, Morningstar says the 5-year average forward multiple has been 10.16x. So, using a 10.5x average forward multiple, we can forecast where PFE would trade if it reverts to its mean valuation: $3.03 EPS x 10.5 = $31.82 2025 target $3.09 EPS x 10.5 = $32.45 2026 target So, on average, the price target is $32.13 if PFE were to rise to its average multiple. That presents a potential upside of +32.6% from today. Dividend Yield Target The same thing is evident with PFE's average dividend yield. Its yield today is 7.09% (i.e., $1.72/$24.23). But, historically, it's been 4.25% (Morningstar), or 4.58% (Yahoo! Finance). So, using an average yield of 4.415%, PFE should be worth +71 % more: $1.72 / 0.0415 = $41.45 or +71.0% more The bottom line is that if PFE were to trade at its historical mean P/E multiple or dividend yield the stock is deeply undervalued. In addition, analysts see the stock as too cheap. Analysts' Target Prices For example, Yahoo! Finance reports that 24 analysts have an average price target of $28.67, or +18% higher. Barchart's mean survey target is $27.81, and Stock Analysis says 14 analysts have an average price target of $29.92, or +23% higher. Moreover, which tracks recent analyst recommendations and write-ups, reports that 17 analysts have an average $32.21 price target. So, on average, these surveys show that analysts believe PFE stock is worth $29.65. That is potentially +22.3% higher than today. Summary Valuation As a result, using these three metrics, PFE stock looks deeply undervalued: P/E based target ……. $32.13 Div Yield target ……… $41.45 Analysts' targets ……. $29.65 Average Target Price … $34.41, or over $10 higher, and a potential upside of +42%. However, there is no guarantee this will happen over the next 12 months. As a result, it makes sense to set a lower buy-in price and get paid while waiting for this to occur. That's what happens when an investor sells short out-of-the-money (OTM) puts in nearby expiry periods. Shorting OTM PFE Put Options for Income For example, look at the Aug. 29 expiration period, which is one month from today. It shows that the $23.00 put option exercise price, which is 5% below today's trading price (i.e., out-of-the-money), has an attractive yield. Since the midpoing premium is 26 cents, that offers a short-seller (i.e., an investor who enters a trade to 'Sell to Open') an immediate 1.13% yield (i.e., $0.26/$23.00 = 0.0113). This also means that even if PFE stock falls to $23.00, the investor has a breakeven point of $23.00-$0.26, or $22.74. That is 6.3% below today's price, providing good downside protection. Moreover, the delta ratio is low at just 24%, implying a low probability that the stock will fall to this strike price over the next month. That implies an investor stands to make an expected return of over 3.3% over the next 3 months if this trade can be repeated. In effect, it allows investors at today's undervalued price to make extra income. In addition, even if PFE falls to $23.00, the investor's potential upside is quite attractive, over +50%: $34.41 target price / $22.74 breakeven point = 1.513 - 1 = +51.3% upside The bottom line here is that PFE stock looks deeply undervalued on a statistical basis. One way to play it is to short OTM puts to generate extra income. On the date of publication, Mark R. Hake, CFA did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
8 hours ago
- Yahoo
Pfizer Stock: Analyst Estimates & Ratings
With a market cap of $138.2 billion, Pfizer Inc. (PFE) is a leading global biopharmaceutical company headquartered in New York City. Founded in 1849, Pfizer discovers, develops and manufactures medicines and vaccines across a broad range of therapeutic areas, including oncology, immunology, rare diseases, cardiology, endocrinology and vaccines. Shares of this pharmaceutical giant have underperformed the broader market over the past year. PFE has declined 21% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 17.1%. In 2025, PFE stock is down 8.4%, compared to SPX's 8.6% rise on a YTD basis. More News from Barchart Tesla Just Signed a Chip Supply Deal with Samsung. What Does That Mean for TSLA Stock? Dear Microsoft Stock Fans, Mark Your Calendars for Aug. 1 Is Lucid Motors Stock a Buy, Sell, or Hold for July 2025? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Zooming in, PFE has also trailed the Invesco Pharmaceuticals ETF (PJP), which has fallen 2.7% over the past year and has surged 1.3% in 2025 On July 24, Pfizer announced a global (excluding China) licensing agreement with 3SBio for exclusive rights to develop, manufacture, and commercialize SSGJ-707, a bispecific antibody targeting PD-1 and VEGF. The deal strengthens Pfizer's oncology pipeline and reinforces its position in innovative cancer research. However, its shares dropped 2.2% in the next trading session amid macroeconomic headwinds. For the current fiscal year, ending in December, analysts expect PFE's EPS to decline 1.3% year over year to $3.07 on a diluted basis. The company's earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters. Among the 22 analysts covering PFE stock, the consensus is a 'Moderate Buy.' That's based on six 'Strong Buy' ratings, one 'Moderate Buy,' 14 'Holds,' and one 'Strong Sell.' This configuration is less bullish than three months ago, when seven analysts suggested a 'Strong Buy.' On April 30, UBS Group AG (UBS) analyst Trung Huynh raised Pfizer's price target from $24 to $25 while maintaining a 'Neutral' rating. Despite mixed revenue performance, the analyst highlighted Pfizer's significant cost savings as a positive factor. The mean price target of $27.81 represents a 14.4% premium to PFE's current price levels. The Street-high price target of $33 suggests an ambitious upside potential of 35.7%. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
